Latest Intellectual Property News

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.

BluGlass Limited reported a 16% rise in revenue to $11.7 million for FY25, driven by key US Department of Defense contracts and new partnerships. However, the company’s net loss increased 8% to nearly $11 million amid ongoing R&D investment and operational scaling.

Blackstone Minerals has entered a strategic joint venture with Vietnam’s Xuan Loc Tho Co. Ltd. to develop the Ta Khoa Nickel Project and Refinery, significantly reducing holding costs while maintaining exposure to nickel’s upside.

Atturra Limited reported a robust 24% increase in FY25 revenue to $300.6 million, driven by cloud services growth and strategic acquisitions. The company eyes over $384 million revenue in FY26, underpinned by expanding proprietary IP and AI investments.

Biome Australia Limited reports its first profitable year since 2018, driven by a 41.6% revenue increase and significant international growth.

PlaySide reports a 25% revenue decline and a $12.1 million net loss in FY25, driven by fewer original IP launches and restructuring costs. The company raises capital and streamlines operations ahead of major 2026 game releases.

PlaySide Studios reported a significant revenue drop and EBITDA loss in FY25, driven by declines in original IP sales. However, the company is banking on new game launches and cost-cutting measures to fuel a turnaround in FY26.

PlaySide Studios reported a 25% revenue decline to $48.7 million for FY25, resulting in a $12.1 million net loss. The company is banking on new game launches and cost savings to reverse the downturn in FY26.

Terragen Holdings reported a $3.72 million loss for FY25, impacted by drought and lower revenues, while launching dry probiotic products targeting feedlots and completing a $4.76 million equity raise.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.